Emerging Biomarkers for Targeted Agents Show Promise in NSCLC
Published: Tuesday, Sep 17, 2019
Alex A. Adjei, MD, PhD
As advancing technologies and novel agents continue to expand treatment strategies in non–small cell lung cancer (NSCLC), the quest to develop more effective therapies targeting NTRK, RET, MET, BRAF, and HER2 is underway, said Alex A. Adjei, MD, PhD.
... to read the full story